The floor-price legitimate KSM-66 — same Ixoreal patent, same trial dose, $14/month.
Nutricost KSM-66 is the floor-price legitimate KSM-66 on Amazon. The Ixoreal patent is real (verify the logo on the back panel — Nutricost is on the authorised buyers list), the dose is the exact 600 mg Wankhede 2015 / Lopresti 2019 trial dose, and the price is $14/month — $8 cheaper than Double Wood for the same active extract. The trade-off is the lab transparency tier: Nutricost runs internal GMP batch QC with supplier docs from Ixoreal, but doesn't publish per-batch COAs the way Double Wood does.
For first-time buyers running an 8-week validation cycle, this trade is the right call — you're paying to verify you're a responder, not to audit every batch's withanolide percentage. Eight weeks, $28 total cost, baseline + post-cycle hormone panel. If you respond, upgrade to Double Wood for cycle two. If you don't, you spent $28 to learn you're a non-responder — cheapest lesson in the supplement world.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete Ashwagandha guide →KSM-66 by Ixoreal Biomed, 5% withanolides root-only full-spectrum extract — the standard KSM-66 specification measured in all 24+ published KSM-66 RCTs. Ixoreal patent logo verified on the bottle back panel; Nutricost is on Ixoreal's published authorised buyers list and has been licensed continuously since 2018. The active extract inside the capsule is IDENTICAL to what's inside Double Wood's bottle — same supplier, same standardisation, same Ixoreal contract. Loses 1 point only because 10% withanolide UHP (Toniiq) is theoretically more concentrated for cycle-two upgrade buyers.
KSM-66 is the most-studied ashwagandha extract on earth — 24+ placebo-controlled RCTs across stress, sleep, testosterone, strength, and cognition. Wankhede 2015 (PMID 26609282) and Lopresti 2019 testosterone (PMID 31517876) both used exactly this extract at exactly this dose. Generic 'ashwagandha extract' bottles can't claim the same evidence base — the trials simply weren't run on them. Nutricost's KSM-66 inherits the entire 24+ RCT evidence base by virtue of carrying the patent. Loses 0.5 because Sensoril has a stronger cortisol/anxiety case at lower mg doses (Auddy 2008) for that specific endpoint.
GMP-certified facility + supplier docs from Ixoreal + internal batch QC — but NO public per-batch Certificate of Analysis. The QC happens (authenticated KSM-66 supply chain + Ixoreal contract guarantees + facility audit), but it's not consumer-accessible the way Double Wood's lookup is. For first-cycle validation buyers this is acceptable risk; for audit-driven users tracking responder data across multi-supplement protocols, the lack of per-batch visibility is the single biggest concession to the budget price. This is the criterion that separates the 8.5 budget tier from the 9.0 trusted-brand tier.
600 mg per single capsule — the EXACT dose used in Wankhede 2015 (testosterone +96 ng/dL), Lopresti 2019 testosterone (+14.7% total T), and Chandrasekhar 2012 (-27.9% cortisol). One cap, one swallow, one day's clinical dose. No splitting, no titration math, no two-capsule pill-load. Matches Double Wood's dose exactly — Nutricost is not 'budget' on the dose dimension, only on the QC documentation dimension. This is what makes the bottle a legitimate cycle-one option rather than a budget compromise.
$14/month at 1 cap/day = $0.23 per 600 mg KSM-66 = ~$0.0078 per mg active withanolide (5% of 600 = 30 mg withanolide/cap). The cheapest legitimate KSM-66 per active mg on the consumer market. Double Wood is $0.012/mg active (53% more); Toniiq UHP is $0.0082/mg active despite higher concentration. Nutricost wins the per-active-mg math against every other patent-verified KSM-66 bottle on the list. Loses 0.5 only because Nature's Bounty (non-standardised whole root) is theoretically cheaper per gram weight, but their lack of standardisation makes the per-active-mg comparison meaningless.
“Made with the most clinically-studied form of ashwagandha — KSM-66.”
KSM-66 has 24+ published placebo-controlled human RCTs as of 2026 — by a wide margin the most-studied standardised ashwagandha extract. The Ixoreal patent logo on the bottle is verifiable; Nutricost is on Ixoreal's published authorised buyers list. The 'most studied form' claim is literal truth.
“Each capsule contains 600 mg of KSM-66 standardised to 5% withanolides.”
600 mg/cap at 5% withanolides standardisation is the contracted KSM-66 specification — Nutricost's supplier docs from Ixoreal verify the standardisation at the extract level. The claim is accurate at the supplier-chain level, even without public per-batch COA verification at the consumer level.
“GMP-certified facility, third-party tested.”
GMP-certified facility — verified. Third-party tested — partially true; batch testing happens at the contract manufacturer, but the COAs are not publicly published. The third-party documentation discipline is below Double Wood's tier (public per-batch COA) and well below Toniiq's tier (NSF facility audit + public per-lot lookup). 'Third-party tested' is technically accurate but creates expectation of consumer-accessible documentation that isn't there.
“Supports natural testosterone, stress response, and energy.”
Verified in stressed, overweight, or resistance-trained populations — Lopresti 2019 measured +14.7% total T at 600 mg/8 weeks in men 40-70; Chandrasekhar 2012 measured -27.9% cortisol at the same dose. NOT verified as a generic T-booster claim for already-healthy men with normal cortisol — the mechanism is cortisol-down, so the T uplift is conditional on having elevated cortisol to suppress. Real claim for the right population.
“Premium quality at an affordable price.”
$14/month for licensed KSM-66 at the trial-exact dose is genuinely the cheapest legitimate KSM-66 on the consumer market. The 'affordable' framing is accurate; the 'premium quality' framing is accurate at the active-extract level (real Ixoreal KSM-66) but partial at the QC documentation level (no public COA). Honest framing for the price tier.
Both Nutricost and Double Wood source KSM-66 from Ixoreal Biomed under the same patent contract. The extract inside the capsule is the same supplier, same standardisation, same Ixoreal-authenticated chain of custody. The $8/month price gap is NOT a quality gap at the extract level — it's a documentation gap at the consumer-accessibility level. Double Wood publishes per-batch COAs with lot-lookup; Nutricost keeps that documentation internal. For first-cycle validation buyers, the documentation gap is small risk. For audit-driven multi-supplement protocols, it's the upgrade trigger.
Counterfeit KSM-66 is the #1 ashwagandha adulteration vector on Amazon — bottles that print 'KSM-66' on the label but ship 1-2% withanolide generic root powder. Nutricost is on Ixoreal's authorised buyers list and the bottle carries the official KSM-66 logo, so this isn't counterfeit. But the LACK of public COA means you can't independently verify your specific bottle's batch matches spec — you're trusting the supplier chain rather than the per-batch test result. For most buyers this is fine; for paranoid validators, Double Wood's $8/month upgrade buys verifiable proof.
Most first-time ashwagandha buyers don't know if they're responders yet. ~20-30% of users don't get meaningful cortisol response (genetics, baseline cortisol, gut absorption variance — multiple factors). Paying $44 for 8 weeks of Double Wood to find out you're a non-responder is more expensive than paying $28 for 8 weeks of Nutricost. The cheapest possible validation cycle for the real KSM-66 patent is what Nutricost delivers — same extract, same dose, $16 less. If you respond, upgrade to Double Wood for the audit-grade COA. If you don't respond, you saved $16 on the lesson.
Some KSM-66 bottles ship 300 mg/cap to enable titration — Jarrow Formulas does this. But for first-cycle validation buyers, titration friction (deciding when to ramp, splitting AM/PM, tracking response across dose levels) adds confounding variables to the responder/non-responder decision. Nutricost's 600 mg single cap gives you the clinical dose in one swallow — no titration math, no compliance friction. The simplicity of the protocol is the actual feature; the budget price is the cherry on top. Test response in 8 weeks at the trial-exact dose, decide based on numbers, not vibes.
Nutricost makes a tongkat ali bottle too — generic standardised extract at 400 mg/cap for $12/month. Stacking Nutricost KSM-66 600 mg + Nutricost Tongkat Ali 400 mg gives you both mechanisms (cortisol-down via ashwagandha HPA-axis suppression + free-T-up via tongkat SHBG displacement) for $26/month total. Compare to running Double Wood KSM-66 + Double Wood LJ100 Tongkat at ~$45/month — the Nutricost stack is 42% cheaper. For budget-constrained first-cycle validation of the full double-lever protocol, this is the smart $26 starting point.
Nutricost KSM-66 wins the 'Best Budget' badge by delivering the same active extract as Double Wood ($8/month cheaper) at the exact 600 mg Wankhede 2015 / Lopresti 2019 trial dose. The Ixoreal patent is real (verify the logo on the back panel; Nutricost is on the authorised buyers list), the dose is trial-exact, the standardisation is contracted at the supplier level. The trade-off is the lab transparency tier — no public per-batch COA, only internal GMP batch QC with supplier docs. For first-cycle validation buyers running an 8-week test to discover whether they're responders, this trade is the smart call: $28 total cost for 8 weeks at the trial-exact dose, pre/post hormone panel. If you respond, upgrade to Double Wood for the audit-grade COA on cycle two. If you don't, you saved $16 vs running Double Wood for the same validation. The 'buy' verdict reflects the specific use case: cycle-one validation on a budget. For audit-driven users tracking responder data across multi-supplement protocols, Double Wood's $8/month upgrade buys per-batch visibility that Nutricost can't match — pay the premium. For cortisol-first / anxiety-first buyers, Life Extension Sensoril ($15/month) wins on the cortisol-per-mg endpoint even at a similar price point. For maxxers chasing the highest withanolide concentration, Toniiq UHP ($32/month) at 10% withanolides is the upgrade. Nutricost wins only when budget validation is the specific job to be done. Upgrade triggers: after the 8-week baseline, if you respond well and want audit-grade documentation, move to Double Wood for cycle two. If you respond well and want to push potency, move to Toniiq UHP. If you didn't respond, verify the Ixoreal logo on your specific bottle (was it real KSM-66?) before concluding you're a non-responder — stack with tongkat ali (Nutricost's tongkat is $12/month) for the cortisol + SHBG double lever, or re-evaluate whether your cortisol was actually elevated baseline.
The cycle-two upgrade at $22/month — same Ixoreal patent, same 600 mg trial dose, but with public per-batch COA + lot-lookup. The right next step after Nutricost validation if you respond well.
See it on the list →The premium upgrade at $32/month — 10% withanolide UHP (2× standard KSM-66) + NSF-grade facility. Worth it if you've validated response and want maximum potency.
See it on the list →Different patent (Sensoril by Natreon, 10% withanolides root + leaf) at the 125 mg Auddy 2008 dose for $15/month. The right pick if cortisol / anxiety is the primary endpoint, not testosterone specifically.
See it on the list →600 mg/day KSM-66 for 8 weeks in resistance-trained men measured serum testosterone +96 ng/dL vs +18 placebo, plus strength gains across bench press and leg extension. The key strength + testosterone trial anchoring Nutricost's 600 mg single-cap protocol.
600 mg/day KSM-66 for 16 weeks in overweight men 40-70 raised total testosterone +14.7% and DHEA-S +18% vs placebo. The cornerstone trial behind the 600 mg dose recommendation for the testosterone endpoint in older / overweight populations.
600 mg/day KSM-66 for 60 days in chronically stressed adults reduced perceived stress -44% and morning serum cortisol -27.9% vs placebo. The headline cortisol-suppression evidence at exactly the Nutricost single-cap dose.
240 mg/day KSM-66 for 60 days lowered morning cortisol -23% and improved sleep quality + DHEA-S +18% vs placebo. Shows the HPA-axis mechanism is sensitive — even at 40% of the Nutricost dose, the cortisol effect lands.
KSM-66 600 mg/day for 8 weeks in healthy adults improved sleep quality scores, reduced anxiety, and lowered morning cortisol. Extends the cortisol/stress evidence from chronically-stressed populations into the broader 'healthy but stressed' demographic that most ashwagandha buyers fall into.
125-250 mg/day Sensoril for 60 days reduced serum cortisol -24.2% and raised DHEA-S +32%. Cited here as the KSM-66-vs-Sensoril context: Sensoril matches KSM-66's cortisol effect at 1/4 the gram dose, but KSM-66's testosterone evidence base is deeper.
